Foundation Medicine, Inc. et al. vs Caris MPI, Inc. et al.

Other: fed circuit mandate

Other: other court decision

Trial Certificate Checklist

JUDGMENT Granting Request for Adverse Judgment on Remand 37 C.F.R. 42.73(b)

Patent Owner's Request for Adverse Judgment

Disclaimer in Patent Under 37 CFR 1.321(a) filed on January 12, 2022

Panel Change Order

Petitioner's Motion for Admission Pro Hac Vice of Jonathan Swisher

Declaration of Jonathan Swisher in Support of Petitioner's Motion for Admission Pro Hac Vice

Petitioner's Updated Exhibit List

Order: Other

PETITIONER'S MOTION FOR WITHDRAWAL OF COUNSEL

PETITIONER'S UPDATED MANDATORY NOTICES

PETITIONER'S POWER OF ATTORNEY

EXPUNGED

Petitioner's Notice of Cross-Appeal

Patent Owner's Notice of Appeal

Termination Decision Document

EXPUNGED

Hearing Transcript

Petitioner's Updated Mandatory Notices

Petitioner's Updated Mandatory Notices And Exhibit List

ORDER Oral Hearing 37 C.F.R. ¿¿ 42.70

Patent Owner's Updated Mandatory Notices

Decision - Granting Patent Owner's Motions for Pro Hac Vice Admission of Jonathan Singer - 37 CFR 42.10

Patent Owner's Sur-Reply

Petitioner's Request for Oral Argument

Patent Owner's Request for Oral Argument

Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Jonathan Singer

Declaration of Jonathan Singer

O'Shaughnessy Deposition Transcript Volume 1 10-22-19

O'Shaughnessy Deposition Transcript Volume 2 10-23-19

Bender LinkedIn Profile

Loesch LinkedIn Profile

Yeakley LinkedIn Profile

Petitioner's Reply to Patent Owner's Response

Chen

Reply Declaration of Paul T. Spellman, Ph.D.

U.S. Pat. No. 9,053,224

File History Excerpt for U.S. Pat. App. No. 12/658,770

Penny LinkedIn Profile

McGinniss LinkedIn Profile

Pawlowski LinkedIn Profile

Alarcon LinkedIn Profile

Wright LinkedIn Profile

Bibikova LinkedIn Profile

Haber NFCR Profile

Sordella Cold Spring Harbor Laboratory Profile

Godin-Heymann LinkedIn Profile

Settleman LinkedIn Profile

Puzanov

Gustin

Mittendorf

Chudin LinkedIn Profile

Kwak LinkedIn Profile

Leyland-Jones NFCR Profile

Riely

PANEL CHANGE ORDER Conduct of the Proceedings 37 C.F.R. ¿¿ 42.5

Patent Owner's Updated Mandatory Notices

Patent Owner's Updated Power of Attorney

Granting Patent Owner's Motions for Pro Hac Vice Admission of Corrin Drakulich

Granting Patent Owner's Motions for Pro Hac Vice Admission of Christina Brown-Marshall

Declaration of Corrin Drakulich

Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Corrin Drakulich

Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Christina Brown-Marshall

Declaration of Christina Brown-Marshall

Petitioner's Notice of Deposition of Joyce A. O'Shaughnessy, M.D.

Petitioner's Updated Mandatory Notices

Decision Granting Petitioner's Motions for Pro Hac Vice Admission of Vinita Ferrera

Ferrera Declaration

Petitioner's Motion For Admission Pro Hac Vice of Vinita Ferrera

Patent Owner's Response

Deposition Transcript of Paul Spellman, Ph.D., Foundation Medicine V. Caris MPI, Inc. July 25, 2019

Expert Declaration of Joyce O¿¿¿Shaughnessy, M.D.

"Dr. Daniel Von Hoff Presented With Top Genomics Award from Scripps" downloaded from the internet at https://www.eurekalert.org/pub_releases/2011-03/ttgrddv031711.php on August 30, 2019

Foundation Medicine, Inc., "Foundation One: Technical Information and Test Overview", downloaded from the internet at www.foundationone.com on March 4, 2019, 2 pages

Hanahan, et al., "The Hallmarks of Cancer," Cell, Vol. 100, 57-70, January 7, 2000

Sorlie, et al., ¿¿¿Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Sets,¿¿¿ PNAS Vol. 100, No. 14, July 8, 2003, pp. 8418-8423.

National Comprehensive Cancer Network, "Gastric Cancer Clinical Practice Guidelines in Oncology", Journal of the National Comprehensive Cancer Network, Vol. 1, No. 1, January 2003, pp. 27-39

National Comprehensive Cancer Network, "Breast Cancer Clinical Practice Guidelines in Oncology", Journal of the National Comprehensive Cancer Network, Vol. 7, No. 2, February 2009, pp. 122-192

Part 1 of 2 - National Comprehensive Cancer Network, "Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology", Journal of the National Comprehensive Cancer Network, Vol. 4, No. 6, July 2006, pp. 547-582

National Comprehensive Cancer Network, "Breast Cancer Version 4.2017 Clinical Practice Guidelines in Oncology", Journal of the National Comprehensive Cancer Network, Vol. 16, No. 3, March 2018, pp. 310-320

The Cancer Genome Atlas Research Network et al., "The Cancer Genome Atlas Pan-Cancer Analysis Project," Nature Genetics, Vol. 45, No. 10, October 2013, pp. 1113-1120

National Comprehensive Cancer Network, "Colon Cancer Version 1.2017 Clinical Practice Guidelines in Oncology", Journal of the National Comprehensive Cancer Network, Vol. 15, No. 3, March 2017, pp. 370-398

Richard Simon, "Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers," Journal of Clinical Oncology, Vol. 23, No. 29, October 10, 2005, pp. 7332-7341

National Comprehensive Cancer Network, "Small Cell Lung Cancer Clinical Practice Guidelines in Oncology", Journal of the National Comprehensive Cancer Network, Vol. 4, No. 6, July 2006, pp. 601-622

Shen et al., "Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing among Patients with Newly Diagnosed Metastatic Lung Cancer," Clinical Lung Cancer, Vol. 18, No. 4, July 2017, pp. e233-e241

Paez et al., "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy," Science, Vol. 304, June 4, 2004, pp. 1497-1500

F Loupakis et. al, "KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer," British Journal of Cancer, Vol. 101, No. 4, July 14, 2009, pp. 715-721

FoundationOne¿¿HEME Technical Specification, downloaded from the internet at https://assets.ctfassets.net/vhribv12lmne/zBxaQC12cScqgsEk8seMO/c32a7d1adf083cb0f5d0c0b2439fdb87/F1H_Technical_Information.pdf on August 28, 2019, 3 pages

FoundationOne¿¿CDX Webpage, downloaded from the internet at https://www.foundationmedicine.com/genomic-testing/foundationone-cdx#overview on August 28, 2019, 12 pages

Part 2 of 2 - National Comprehensive Cancer Network, "Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology", Journal of the National Comprehensive Cancer Network, Vol. 4, No. 6, July 2006, pp. 547-582

Corless et al., "Tackling Formalin-Fixed, Paraffin-Embedded Tumor Tissue with Next-Generation Sequencing," Cancer Discovery, January 12, 2012, pp. 23-24

Gleevec¿¿ FDA 2001 Approval Letter downloaded from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021335 on August 19, 2019, 3 pages

Leslie A. Pray, "Gleevec¿¿: The Breakthrough in Cancer Treatment," Nature Education, Vol. 1, 2008, 4 pages

Gleevec¿¿ FDA 2002 Approval Letter downloaded from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021335 on August 19, 2019, 4 pages

Avastin¿¿, Highlights of Prescribing Information downloaded from the internet at https://www.gene.com/download/pdf/avastin_prescribing.pdf on August 15, 2019, 39 pages

Von Hoff et al., "Frequency of Potential Therapeutic Targets Identified by IHC and DNA Microarray in Tumors From Patients Who Have Progressed on Multiple Therapeutic Agents," Journal of Clinical Oncology, Vol. 24, No. 18. Suppl.3

Foundation Medicine, Inc., Form 10-K, filed March 3, 2017 for the period ending December 31, 2016

Gleevec¿¿ Label, downloaded from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021335 on August 19, 2019, 22 pages

Lynch et al., "Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib," NEJM, Vol. 350, May 20, 2004, Abstract

Pao et al., "EGF receptor gene mutations are common in lung cancers from ¿¿¿never smokers¿¿¿ and correlate with sensitivity of tumors to gefitinib (Iressa) and erlotinib (Tarceva)," PNAS, Vol. 101, No. 36, September 7, 2004, pp. 13306-13311

Kari et. al, "Targeting the Epidermal Growth Factor in Cancer," Cancer Research, Vol. 63, January 1, 2003, pp. 1-5

Tanner et. al, "Amplification of HER-2 in Gastric Carcinoma," Annals of Oncology, Vol. 16, 2005, pp. 273-278

Flavell, "Keytruda," Immuno-Oncology News, downloaded from the internet at https://immuno-oncologynews.com/keytrudapembrolizumab/ on August 15, 2019, 8 pages

Yang, "Epidemiology of Lung Cancer Prognosis: Quantity and Quality of Life," Methods Mol Biol., September 17, 2010, Vol. 471, pp. 1-17

Azzoli et. al, "American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small Cell Lung Cancer," ASCO, January 2010, pp. 39-43

Fuest, "Dan Von Hoff¿¿¿s Karnofsky Lecture: Smart Phase I Trials Can Extend Life Beyond ¿¿¿The Last 12 Weeks,'" Oncology Times ASCO Meeting Reporter Supplement, August 10, 2010, pp. 21-23

Haber et al., "Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors," Cold Spring Harbor Laboratory Press, Vol. LXX, 2005, pp. 419-426

Sartore-Bianch et al., "PIK3CA Mutations in Colorectal Cancer Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies," Cancer Research, Vol. 69, No. 5, March 1, 2009, pp. 1851-1857

Black et al., "Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells", Clinical Cancer Research, Vol. 14, No. 5, March 1, 2008, pp.1478-1486

FoundationOne¿¿Liquid Technical Specification, downloaded from the internet at https://assets.ctfassets.net/vhribv12lmne/3SPYAcbGdqAeMsOqMyKUog/d0eb51659e08d733bf39971e85ed940d/F1L_TechnicalInformation_MKT-0061-04.pdf on August 28, 2019, 2 pages

Patent Owner's Cancellation of Deposition

Patent Owner's Notice of Deposition of Mark Abramovitz, Ph.D

Declaration of Sylvia Hall-Ellis, Ph.D.

Joint Stipulation to Modify Due Dates 1-3

Decision Granting Petitioner's Motions for Pro Hac Vice Admission of Shirley X. Li Cantin

Decision Granting Petitioner's Motions for Pro Hac Vice Admission of David B. Bassett

Granting Petitioner's Motion to File Supplemental Information

Exhibit 3003

Petitioner's Updated Mandatory Notices

ORDER Conduct of the Proceeding

Exhibit 3002

Corrected Affidavit of Christopher Butler

Declaration Of Shirley X. Li Cantin In Support Of Motion For Admission Pro Hac Vice

Petitioners Motion For Admission Pro Hac Vice Of David B. Bassett

Declaration Of David B. Bassett In Support Of Motion For Admission Pro Hac Vice

Petitioners Motion For Admission Pro Hac Vice Of Shirley X. Li Cantin

Patent Owner's Opposition to Petitioner's Motion to Submit Supplemental Information

EXPUNGED

Mark Abramovitz et al.

Motion to Submit Supplemental Information

Declaration of Mark Abramovitz

Jian-Bing Fan et al.

Sunnybrook Seminar Notice

EXPUNGED

EXPUNGED

EXPUNGED

Bio-It World

Illumina Seminar Notice

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

Order - Conduct of the Proceedings - 37 CFR 42.5

Notice of Deposition of Paul T. Spellman, Ph.D

Patent Owner's Objections to Evidence

Trial Instituted Document

Scheduling Order

PANEL CHANGE ORDER Conduct of the Proceedings 37 C.F.R. ¿¿ 42.5

Patent Owner's Sur-Reply to Petitioner's Reply

Petitioner's Reply to Patent Owner's Preliminary Response

Conduct of the Proceeding

Ex. 3001

Patent Owner's Preliminary Response

Wakelee, et al Optimizing First-Line Treatment Options for Patience with Advanced NSCLC

National Comprehensive Cancer Network, Breast Cancer Clinical Practice Guidelines in Oncology

Leyland-Jones, Trastuzumab: Hopes and Realities

National Comprehensive Cancer Network, Colon Cancer Clinical Practice Guidelines in Oncology

Declaration of Sandeep K. Reddy, submitted during prosecution of U.S. Patent App. 14/249,261

Horstmann, et al Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002

Declaration of Michael Castro, submitted during prosecution of U.S. Patent App. 11/750,721

Benson, et al American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

U.S. Patent No. 8,880,350

U.S. Patent No. 9,372,193

U.S. Patent No. 9,383,365

Seena Magowitz Foundation, Dr. Daniel Von Hoff Wins ASCO Award

Von Hoff, Pilot Study Using Molecular Profiling of Patients Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Doroshow, et al. Selecting Systemic Cancer Therapy One Patient at a Time Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors?

Patent Owner's Mandatory Notices

Patent Owner's Power of Attorney

Notice of Accord Filing Date

Foundation Medicine, Inc. Power of Attorney

Robert Langreth and Michael Waldholz, New Era of Personalized Medicine Targeting Drugs For Each Unique Genetic Profile, 4 The Oncologist 426 (1999)

Charles Sawyers, Targeted cancer therapy, 432 Nature 294 (2004)

NHGRI Seeks Next Generation of Sequencing Technologies (Oct. 14, 2004), https://www.genome.gov/12513210/

Jackson B. Gibbs, Anticancer drug targets: growth factors and growth factor signaling, 105 J. Clinical Investigation 9 (2000)

Iressa (gefitinib) Prescribing Information (May 2, 2003)

Tarceva (erlotinib) Prescribing Information (Nov. 18, 2004)

Genomics and Personalized Medicine Act of 2006, S. 3822, 109th Cong.

Nida Iqbal & Naveed Iqbal, Imatinib- A Breakthrough of Targeted Therapy in Cancer, Chemotherapy Research & Practice 1 (2014)

Herceptin (trastuzumab) Prescribing Information (Sept. 1998)

S. Scholl, Targeting HER2 in Other Tumor Types, 12 Annals Oncology S81 (2001)

James Moyer et al., Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase, 57 Cancer Research 4838 (1997)

ClinicalTrials.gov, Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma, available at https-//clinicaltrials.gov/ct2/show/NCT01515137

Henry Q. Xiong & James L. Abbruzzese, Epidermal growth factor receptor-targeted therapy for pancreatic cancer, 29 Seminars in Oncology 31 (2002)

NCI Drug Dictionary, https-//www.cancer.gov/publications/dictionaries/cancer-drug/def/cetuximab

Erbitux (cetuximab) Prescribing Information (Feb. 12, 2004)

Erbitux (cetuximab) Prescribing Information (Mar. 1, 2006)

Atul J. Butte et al., Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks, 97 PNAS 12182 (2000)

Jane E. Staunton et al., Chemosensitivity prediction by transcriptional profiling, 98 PNAS 10787 (2001)

Thomas M. Daly et al., Precision Profiling and Components of Variability Analysis for Affymetrix Microarray Assays Run in a Clinical Context, 7 J. Molecular Diagnostics 404 (2005)

Thomas Jarvie, Next generation sequencing technologies, 2 Drug Discovery Today- Technologies 255 (2005)

Daniel R. Rhodes et al., Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression, 25 PNAS 9309 (2004)

H. Parkinson, ArrayExpress a public repository for microarray gene expression data at the EBI, 33 Nucleic Acids Research D553 (2005)

C.J. Zheng et al., TRMP: a database of therapeutically relevant multiple pathways, 20 Bioinformatics 2236 (2004)

Daniel R. Rhodes et al., Oncomine- A Cancer Microarray Database and Integrated Data-Mining Platform, 6 Neoplasia 1, 1 (2004)

Daniel R. Rhodes et al., Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles, 9 Neoplasia 166 (2007)

Jeremy Gollub et al., The Stanford Microarray Database - data access and quality assessment tools, 31 Nucleic Acids Research 94 (2003)

Alexander Statnikov et al., GEMS: A System for Automated Cancer Diagnosis and Biomarker Discovery from Microarray Gene Expression Data, 74 International J. Med. Informatics 491 (2005)

Timothy R. Hughes et al., Functional Discovery via a Compendium of Expression Profiles, 102 Cell 109 (2000)

Xiaojun Zhao et al., Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis, 65 Cancer Research 5561 (2005)

HUGO Gene Nomenclature Committee Symbol Report: EGFR, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:3236

Jian-Bing Fan et al., A Versatile Assay for High-Throughput Gene Expression Profiling on Universal Array Matrices, 14 Genome Research 878 (2004)

Jeffrey S. Ross & Geoffrey S. Ginsburg, The Integration of Molecular Diagnostics with Therapeutics: Implications for Drug Development and Pathology Practice, 119 Am. J. Clinical Pathology 26 (2003) (Ross)

X. Chen et al., TTD: Therapeutic Target Database, 30 Nucleic Acids Research 412 (2002)

S. Forbes et al., COSMIC 2005, 94 British J. Cancer 318 (2006)

Justin Lamb et al., The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease, 313 Science 1929 (2006)

U.S. Provisional Patent Application No. 60/747,645

Oxford Dictionary of Biochemistry and Molecular Biology (Oxford University Press, 2d ed. 2006)

HUGO Gene Nomenclature Committee Symbol Report: ERBB2, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:3430

Business Wire, Illumina Launches DASL Assay and Cancer Panel for Gene Expression Profiling of Paraffin-Embedded Samples (Jan. 13, 2005)

Marina Bibikova et al., Gene Expression Profiles in Formalin-Fixed, Paraffin-Embedded Tissues Obtained with a Novel Assay for Microarray Analysis, 50 Clinical Chemistry 2384 (2004)

Marina Bibikova et al., Quantitative Gene Expression Profiling in Formalin-Fixed, Paraffin-Embedded Tissues Using Universal Bead Arrays, 165 American J. Pathology 1799 (2004)

David S. Wishart et al, DrugBank: a comprehensive resource for in silico drug discovery and exploration, 34 Nucleic Acids Research D668 (2006)

Timothy K. Egan, Monitoring Patients Undergoing Cancer Therapy, 31 Lab. Med. 666 (2000)

HUGO Gene Nomenclature Committee Symbol Report: ESR1, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:3467

NIH National Cancer Institute, How Imatinib Transformed Leukemia Treatment and Cancer Research, (updated Apr. 11, 2018) https://www.cancer.gov/research/progress/discovery/gleevec

Claudia Dreifus, Researcher Behind the Drug Gleevec, N.Y. Times (Nov. 2, 2009), at D4

Masuko Katoh & Masaru Katoh, Bioinformatics for Cancer Management in the Post-Genome Era, 5 Technology in Cancer Research & Treatment 169 (2006)

David Stipp, Gene Chip Breakthrough, Fortune Magazine, Mar. 31, 1997, at 56

Jian-Bing Fan et al., BeadArray-based solutions for enabling the promise of pharmacogenomics, 39 BioTechniques 583 (2005)

U.S. Patent No. 9,092,392 (the 392 patent)

G. William Moore et al., A Prototype Internet Autopsy Database: 1625 Consecutive Fetal and Neonatal Autopsy Facesheets Spanning Twenty Years, 120 Archives Pathology Lab. Med. 782 (1996)

HUGO Gene Nomenclature Committee Symbol Report: CASP8, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:1509

Phillip G. Febbo & Geoffrey S. Ginsburg, Personalized diagnostic and therapeutic strategies in oncology, 2 Personalized Medicine 97 (2005)

Dan L. Longo, Imatinib Changed Everything, 376 New England J. Med. 982 (2017)

Federico Cappuzzo et al., Clinical experience with gefitinib: An update, 58 Critical Reviews in Oncology/Hematology 31 (2006)

Complaint

Andreas Gnirke et al., Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing, 27 Nature Biotechnology 182 (2009)

Timothy Ley et al., DNA sequencing of a cytogenetically normal acute myeloid leukemia genome, 456 Nature 66 (2008)

Ashish Gautam et al., RRM1-induced metastasis suppression through PTEN-regulated pathways, 22 Oncogene 2135 (2003)

HUGO Gene Nomenclature Committee Symbol Report: CTNNB1, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:2514

U.S. Patent No 8,768,629 (the 629 patent)

Degeng Wang, Discrepancy between mRNA and protein abundance: Insight from information retrieval process in computers, 32 Computational Biology & Chemistry 462 (2008)

Yardena Samuels et al., High Frequency of Mutations of the PIK3CA Gene in Human Cancers, 304 Science 554 (2004)

Hong-Guang Xie & Felix W. Frueh, Pharmacogenomics steps toward personalized medicine, 2 Personalized Medicine 325 (2005)

David J. Sugarbaker et al., Transcriptome sequencing of malignant pleural mesothelioma tumors, 105 PNAS 3521 (2008)

Andreas Gnirke et al., Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing, 27 Nature Biotechnology 182, Supplementary Figures and Tables (2009)

U.S. Patent Publication No. 2008/0014146 (Von Hoff)

Alberto Bardelli & Victor E. Velculescu, Mutational analysis of gene families in human cancer, 15 Current Opinion in Genetics & Development 5 (2005)

ThermoFisher Scientific, Overview of Immunohistochemistry (IHC)

HUGO Gene Nomenclature Committee Symbol Report: PIK3CA, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:8975

Gerold Bepler, Pharmacogenomics: A reality or still a promise?, 54 Lung Cancer S3 (2006)

HUGO Gene Nomenclature Committee Symbol Report: BRAF, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:1097

HUGO Gene Nomenclature Committee Symbol Report: RAF1, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:9829

Tobias Sjoblom et al., The Consensus Coding Sequences of Human Breast and Colorectal Cancers, 314 Science 268, Supporting Material (2006), available at http://science.sciencemag.org/content/suppl/2006/10/24/1133427. DC1

Tobias Sjoblom et al., The Consensus Coding Sequences of Human Breast and Colorectal Cancers, 314 Science 268 (2006)

Tobias Sjoblom et al., The Consensus Coding Sequences of Human Breast and Colorectal Cancers, 314 Science 268, Table S1 (2006), available at http://science.sciencemag.org/content/suppl/2006/10/24/1133427. DC1

Tobias Sjoblom et al., The Consensus Coding Sequences of Human Breast and Colorectal Cancers, 314 Science 268, Table S3 (2006), available at http://science.sciencemag.org/content/suppl/2006/10/24/1133427. DC1

Tobias Sjoblom et al., The Consensus Coding Sequences of Human Breast and Colorectal Cancers, 314 Science 268, Table S5 (2006), available at http://science.sciencemag.org/content/suppl/2006/10/24/1133427. DC1

Tobias Sjoblom et al., The Consensus Coding Sequences of Human Breast and Colorectal Cancers, 314 Science 268, Table S6 (2006), available at http://science.sciencemag.org/content/suppl/2006/10/24/1133427. DC1

Olena Morozova & Marco A. Marra, Applications of next-generation sequencing technologies in functional genomics, 92 Genomics 255 (2008)

Tobias Sjoblom et al., The Consensus Coding Sequences of Human Breast and Colorectal Cancers, 314 Science 268, Tables S2A and S2B (2006), available at http://science.sciencemag.org/content/suppl/2006/10/24/1133427. DC1

Tobias Sjoblom et al., The Consensus Coding Sequences of Human Breast and Colorectal Cancers, 314 Science 268, Table S4 (2006), available at http://science.sciencemag.org/content/suppl/2006/10/24/1133427. DC1

U.S. Provisional Application No. 61/170,565

U.S. Provisional Application No. 61/105,335

HUGO Gene Nomenclature Committee Symbol Report- KIT, available at https-//www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC-6342

HUGO Gene Nomenclature Committee Symbol Report- KRAS, available at https-//www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC-6407

Affidavit of Christopher Butler

U.S. Provisional Application No. 61/217,289

Amy L. McDoniels-Silvers et al., Differential Expression of Critical Cellular Genes in Human Lung Adenocarcinomas and Squamous Cell Carcinomas in Comparison to Normal Lung Tissues, 4 Neoplasia 141 (2002)

PCT Publication No. WO 03/017038 (published Feb. 27, 2003) (Lu)

Illumina Gene Expression Profiling, Technical Bulletin, RNA Profiling with the DASL Assay (2005) (Illumina)

U.S. Patent Publication No. 2002/0150966 (Muraca)

U.S. Patent No. 9,292,660 to Von Hoff et al. (660 patent)

File History Excerpt

Gleevec (imatinib mesylate) Prescribing Information (Jan. 2002)

Fee Authorization

Declaration of Paul T. Spellman, Ph.D.

Petition for Inter Partes Review of U.S. Patent No. 9,292,660